Vermillion to Present at the 30th Annual ROTH Conference

AUSTIN, Texas, March 07, 2018 -- Vermillion, Inc. (Nasdaq:VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that Valerie Palmieri, President and Chief Executive Officer, and Robert Beechey, Chief Financial Officer, are scheduled to participate in the 30^th Annual ROTH Conference, taking place March 11-14 at the Ritz Carlton Hotel in Laguna Niguel, California. 

Presentation Details
Date:               Tuesday, March 13
Time:              3:30pm Pacific Time/6:30pm Eastern Time
Location:         Blue – Salon 2

About Vermillion
Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women with serious diseases.  The company's initial in vitro diagnostic test, OVA1® (MIA), was the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. In March 2016, Vermillion received FDA clearance for Overa™, a Multivariate Index Assay 2nd Generation (MIA2G) test with significantly improved specificity and ease of use. For additional information, including published clinical trials, visit www.vermillion.com. 

Investor Relations Contact:
Jeremy Feffer
LifeSci Advisors LLC
Tel 212-915-2568
[email protected]